HCM
CLVS

Highlander Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Highlander Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-300
Closed -$25K – 764
2017
Q3 		$25K Buy
+300
New +$23.8K 0.02% 466
2015
Q2 		– Sell
-300
Closed -$22K – 867
2015
Q1 		$22K Hold
300
– – 0.02% 537
2014
Q4 		$17K Buy
+300
New +$15.8K 0.01% 589

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Highlander Capital Management's CLVS Position: Q4 2017 in Review

Highlander Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 300 shares — an estimated $25K sold.

Highlander Capital Management first reported a position in CLVS in Q4 2014 and held it in 3 quarters. The position peaked at $25K in Q3 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • Highlander Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
  • Highlander Capital Management sold 300 Clovis Oncology, Inc. shares in Q4 2017, an estimated $25K.
  • Highlander Capital Management first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 3 quarters.
  • Highlander Capital Management's Clovis Oncology, Inc. position peaked at $25K in Q3 2017.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on Highlander Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.